Biogen Pharmachem Industries (531752) Q2 24/25 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter and half year ended 30 September 2024 at the meeting on 13 November 2024.

Financial highlights

• Reported a net loss of ₹99.73 lakh for Q2 FY25, compared to a net profit of ₹72.03 lakh in Q2 FY24.

• Total income for Q2 FY25 was ₹65.05 lakh, down from ₹75.67 lakh in Q2 FY24.

• For the half year ended 30 September 2024, net loss stood at ₹115.56 lakh versus a net profit of ₹112.70 lakh in the prior year period.

• Basic and diluted EPS for Q2 FY25 was (₹0.02), compared to ₹0.01 in Q2 FY24.

Key financial ratios and metrics

• Paid-up equity share capital remained at ₹6,526.03 lakh as of 30 September 2024.

• Other equity declined to (₹989.55) lakh from (₹873.99) lakh as of 31 March 2024.